Literature DB >> 14695179

Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells.

Charles S Cobbs1, Thomas R Whisenhunt, Duane R Wesemann, Lualhati E Harkins, Erwin G Van Meir, Minu Samanta.   

Abstract

Malignant gliomas are the most common primary brain tumors in adults, and the most malignant form, glioblastoma multiforme (GBM), is usually rapidly fatal. Most GBMs do not have p53 mutations, although the p53 tumor suppressor pathway appears to be inactivated. GBMs grow in a hypoxic and inflammatory microenvironment, and increased levels of the free radicals nitric oxide (NO) and superoxide () occur in these malignancies in vivo. Peroxynitrite (ONOO(-)) is a highly reactive molecule produced by excess NO and that can posttranslationally modify and inactivate proteins, especially zinc finger transcription factors such as p53. We demonstrated previously that GBMs have evidence of tyrosine nitration, the "footprint" of peroxynitrite-mediated protein modification in vivo, and that peroxynitrite could inhibit the specific DNA binding ability of wild-type p53 protein in glioma cells in vitro. Here we show that both authentic peroxynitrite and SIN-1 (3-morpholinosydnonimine hydrochloride), a molecule that decomposes into NO and to form peroxynitrite, can inhibit wild-type p53 function in malignant glioma cells. Concentrations of peroxynitrite associated with a tumor inflammatory environment caused dysregulation of wild-type p53 transcriptional activity and downstream p21(WAF1) expression.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695179

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  50 in total

Review 1.  Catalytic antioxidants to treat amyotropic lateral sclerosis.

Authors:  John P Crow
Journal:  Expert Opin Investig Drugs       Date:  2006-11       Impact factor: 6.206

2.  Antioxidant enzymes in oligodendroglial brain tumors: association with proliferation, apoptotic activity and survival.

Authors:  Sally Järvelä; Järvelä Sally; Helena Bragge; Bragge Helena; Niina Paunu; Paunu Niina; Timo Järvelä; Järvelä Timo; Leo Paljärvi; Paljärvi Leo; Hannu Kalimo; Kalimo Hannu; Pauli Helén; Helén Pauli; Vuokko Kinnula; Kinnula Vuokko; Ylermi Soini; Soini Ylermi; Hannu Haapasalo; Haapasalo Hannu
Journal:  J Neurooncol       Date:  2006-04       Impact factor: 4.130

Review 3.  Mitochondrial superoxide dismutase--signals of distinction.

Authors:  Sumitra Miriyala; Aaron K Holley; Daret K St Clair
Journal:  Anticancer Agents Med Chem       Date:  2011-02       Impact factor: 2.505

4.  Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1.

Authors:  Dan Zhu; Stephen B Hunter; Paula M Vertino; Erwin G Van Meir
Journal:  Cancer Res       Date:  2011-07-01       Impact factor: 12.701

5.  Loss of CD4 T-cell-dependent tolerance to proteins with modified amino acids.

Authors:  Varun Gauba; Jan Grünewald; Vanessa Gorney; Lisa M Deaton; Mingchao Kang; Badry Bursulaya; Weijia Ou; Richard A Lerner; Christian Schmedt; Bernhard H Geierstanger; Peter G Schultz; Teresa Ramirez-Montagut
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-18       Impact factor: 11.205

6.  Function of neuronal nitric oxide synthase enzyme in temozolomide-induced damage of astrocytic tumor cells.

Authors:  Fernando Francisco Borges Resende; Simoneide Souza Titze-de-Almeida; Ricardo Titze-de-Almeida
Journal:  Oncol Lett       Date:  2018-02-01       Impact factor: 2.967

7.  Role of nitric oxide and its metabolites as potential markers in lung cancer.

Authors:  Fares Masri
Journal:  Ann Thorac Med       Date:  2010-07       Impact factor: 2.219

Review 8.  Nitric oxide and cancer: a review.

Authors:  Sheetal Korde Choudhari; Minal Chaudhary; Sachin Bagde; Amol R Gadbail; Vaishali Joshi
Journal:  World J Surg Oncol       Date:  2013-05-30       Impact factor: 2.754

Review 9.  iNOS: a potential therapeutic target for malignant glioma.

Authors:  A Jahani-Asl; A Bonni
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

10.  Microarray-based analysis of gene regulation by transcription factors and microRNAs in glioma.

Authors:  Junchi Yu; Xuejian Cai; Jianqing He; Wei Zhao; Qiang Wang; Bin Liu
Journal:  Neurol Sci       Date:  2012-12-05       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.